- Company
- Leclaza’s lightning fast listing shocks global competitors
- by Eo, Yun-Ho Jan 27, 2021 06:15am
- As Yuhan Corporation dashes for the National Health Insurance (NHI) reimbursement talk on Leclaza (lazertinib), affected multinational pharmaceutical companies are tensing up. A Korean-made new drug Leclaza is to get reviewed by the Cancer Deliberation Committee in February, the related industry sees that the non-small cell lung cancer (
- Company
- NOAC prescription market growth stagnates
- by Kim, Jin-Gu Jan 27, 2021 06:15am
- The novel oral anticoagulant (NOAC) market seems to be plateauing after enjoying consistent two-digit growth for years. The outpatient prescription market marked a growth of almost 20 percent until 2019, but the growth shrunk down to 3 percent last year. Regardless of the decreased growth, Lixiana is still topping the market. Except for the
- Company
- 11 companies won consecutive patent disputes for Betmiga
- by Kim, Jin-Gu Jan 27, 2021 06:15am
- In the patent dispute over Betmiga PR (Mirabegron), an overactive bladder treatment with an annual prescription amount of ￦65 billion, generic companies won the first trial. From the standpoint of generic companies, including Hanmi and Chong Kun Dang, which have already launched generics, and are about to release generics, the obstacles r
- Company
- Sales of Statin-Ezetimibe combination have risen sixfold
- by Chon, Seung-Hyun Jan 27, 2021 02:21am
- In the dyslipidemia treatment market, the combination drug market that combines 'Statin' and Ezetimibe' showed rapid growth. Despite COVID-19 outbreak, the sales continued high. In the past five years, sales have increased by six times. Hanmi's Rosuzet and MSD's Atozet led the uptrend. According to the drug research institute UBIST on the
- Company
- Yuhan’s Leclaza zooms through the NHI listing process
- by Eo, Yun-Ho Jan 26, 2021 06:00am
- Yuhan Corporation’s new drug Leclaza could break the record of receiving the National Health Insurance reimbursement the fastest as an anticancer treatment. After the South Korean health authority approved of the drug on Jan. 18, the company immediately entered a talk to list the drug. The pharmaceutical industry source reported the Hea
- Company
- Antidiabetic DPP-4 inhibitor breaks record of KRW 600 bn
- by Kim, Jin-Gu Jan 26, 2021 06:00am
- The outpatient prescription volume of antidiabetic dipeptidyl peptidase 4 (DPP-4) inhibitors exceeded over 600 billion won for the first time in the history. The market is steadfastly growing with about 6 percent surge from last year. The experts hint the oral antidiabetic drug market was the key to the growth. The sodium-glucose cotransport
- Company
- KRW 15M incentive to employees assigned to Organon
- by Jan 25, 2021 06:21am
- MSD Korea has promised to pay out an incentive of 15 million won and maintain the employee benefits for those who were notified to be transferred to a new subsidiary, Organon Korea. A pharmaceutical industry source reported today that MSD Korea has signed an agreement with the labor union on Jan. 22 after a long negotiation. First, M
- Company
- Evenity can be prescribed at general hospitals
- by Eo, Yun-Ho Jan 25, 2021 06:21am
- According to related industries, Amgen's bone formation promotion and bone resorption inhibitor Evenity (Romosozumab) has so far been prescribed in Big 5 general hospitals such as SMC, SNUH, Seoul St. hospital, AMC, and Shinchon Severance Hospital, and has passed the drug commitee (DC) of about 30 medical institutions such as Gangnam Severan
- Company
- KanghanLaw scouted Adviser Jaehong Kwon from BMS Korea
- by Eo, Yun-Ho Jan 25, 2021 06:21am
- KanghanLaw hired Jaehong Kwon (60 yrs old), an advisor from BMS, a multinational pharmaceutical company. According to the industry, former chief executive Jaehong Kwon, who retired from Korea BMS in August last year, officially joined KanghanLaw on January 1st. Adviser Kwon is an industry veteran with 34 years of experience who joined J
- Company
- ↑sales of chronic disease drugs & ↓sales of antibiotics
- by Chon, Seung-Hyun Jan 22, 2021 06:28am
- Despite COVID-19 epidemic, the chronic disease treatment market continued to grow. The market for antibiotics and expectorants declined significantly due to the decrease in cold patients due to strengthening hygiene management. According to UBIST, a drug research institute on the 19th, the prescription amount of statin drugs used to treat dys
